3D Cell Technology
Practical Microfluidics for Bioanalysis
3D Cell Technology
How it works
All assay reagents and organoids are loaded into the Pu•MA System 3D Flowchip wells. The flowchips are placed into the the Pu•MA System. Automated reagent exchange takes place through microfluidic channels and controlled by the Pu·MA System.
Types of assay workflows
This technology can enable a range of assay workflows that result in multiparametric readouts from 3D cell models and organoids.
- In Situ Supernatant Sampling
- Metabolomics Workflow
- Sequential Drug Addition
- Immunofluorescence Workflow
In Situ Supernatant Sampling
Organoids, media and reagents are loaded into the flowchips. The Pu·MA System performs the automated steps described below in the workflow. Read the application note on multiparametric analysis from 3D cell models with compound treatment supernatant sampling supernatant and content imaging.
Spheroids or organoids, media and metabolites are loaded into the flowchips. The Pu·MA System performs the automated steps described below in the workflow. Once the automated treatment steps are completed, the organoids can be lysed in situ for downstream Mass Spectrometry analysis.
Read about single spheroid metabolomics in the application note.
Sequential Drug Addition
Organoids, media and reagents are loaded into the flowchips. The Pu·MA System performs the protocol described below. Different concentrations of drug or compound can be added sequentially via automated steps, during which the samples can be visualized or measurements taken with minimal disruption to the organoid samples.
Read the application note on sequential drug addition to neurospheroids to measure calcium oscillations.
Immunofluorescence for Biomarker Detection
Biomarker detection in organoids, spheroids or tumoroids can be performed using immunofluorescence as shown in the workflow below.
Organoids, primary antibody, secondary antibody, washes and nuclear staining are all loaded into the flowchips. Automated steps are performed within the Pu·MA System.
Applications with Pu•MA System 3D
- Oncology: Automated organoid assays, in situ sampling and in situ imaging
- Toxicology: Toxicity testing in spheroids with in situ imaging
- Metabolism: Pu·MA System 3D for single spheroids assays and downstream metabolomics
- Neuroscience: Phenotypic response to sequential drug addition and analysis in neurospheroids
Watch our webinar with Molecular Devices to learn more about the Pu·MA System 3D capabilities and applications
Jul 9, 2020 Protein Fluidics' Organoid Research Award: Prof. Matthew E. Burow & team (Tulane Univ)
Jan 25, 2020 Protein Fluidics launches Pu·MA System 3D for automated organoid assays
December 4, 2018 Protein Fluidics partners with BioLegend to provide Assay Products
May 4, 2018 Protein Fluidics announces the Pu·MA system
October 1, 2016 Protein Fluidics moves into new headquarters in Burlingame, CA
April 6, 2016 Protein Fluidics closes Series seed round of investment
For Research Use Only. Not for diagnostic use. Protein Fluidics, Protein Fluidics Logo and Pu•MA System are registered trademarks of Protein Fluidics, Inc. in the United States and internationally. All rights reserved. © 2021 PROTEIN FLUIDICS, INC.